Oxford GlycoSciences Plc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oxford GlycoSciences Plc

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jongmans who wrote (88)	12/19/2000 10:04:41 AM
From: nigel bates	Read Replies (1) of 469

Martin, you guys in Europe are just way ahead of us in the US (g). Now there's a NASDAQ symbol, can we get it added to the thread ? The details... Dec. 19 /PRNewswire/ -- Oxford GlycoSciences Plc (Nasdaq: OGSI - news; LSE: OGS) today announced the signing of a research agreement with Pfizer (NYSE: PFE - news) under the terms of which OGS will apply its industrial scale proteomics technology to the discovery of new biomarkers and drug development targets in Alzheimer's disease and atherosclerosis. The collaboration is a continuation of the joint research collaboration entered into between the two companies in April 1998. Under the new agreement, Pfizer will provide further research funding to OGS and pay success related milestone payments. Additionally, OGS will grant Pfizer a non-exclusive license to use OGS's CSF Proteome and Serum Proteome databases. As with the April 1998 agreement, Pfizer will again make an equity investment in OGS. Biomarkers are expected to play a growing role in improving the efficiency of drug development by allowing more objective measures of therapeutic impact to be traced in clinical studies. This is likely to be most useful in diseases such as Alzheimer's disease and atherosclerosis which develop slowly and which therefore require large-scale clinical trials to measure therapeutic effect. Professor Raj Parekh, Chief Scientific Officer of OGS said, ``We are pleased to be continuing our research in Alzheimer's disease and atherosclerosis with Pfizer. This programme allows for OGS and Pfizer to focus on validating biomarkers discovered in our ongoing joint research as well as continuing to search for potential new targets in these two important diseases. We've added our CSF and Serum Proteome databases to the collaboration to speed the discovery of novel markers and targets.''

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next